Prana has applied and received orphan designation in Europe since FDA orphan designation. They have stated that "Prana will continue to work with the US Food and Drug Administration and other agencies to initiate a Phase 3 trial for PBT2 to treat Huntington disease. PBT2 for the treatment of Huntington disease was recently granted Orphan designation in Europe and was granted Orphan designation in the US in 2014. " I think this shows that they are working hard to get the partial hold removed by are also talking to Europe as an alternative lead if FDA doesn't come around.
- Forums
- ASX - By Stock
- ATH
- Ann: Safety Outcomes of Alzheimer's IMAGINE Extension Trial
Ann: Safety Outcomes of Alzheimer's IMAGINE Extension Trial, page-29
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $8.75K | 1.75M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
59 | 63306661 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 28430837 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
57 | 62431661 | 0.004 |
47 | 46138652 | 0.003 |
17 | 39764402 | 0.002 |
13 | 92470101 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 28430837 | 21 |
0.006 | 34263249 | 13 |
0.007 | 22226649 | 17 |
0.008 | 14274594 | 13 |
0.009 | 6000000 | 5 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |